RESUMO
BACKGROUND: Cellulite is a condition characterized by dimpling and contour irregularities in the gluteal and thigh regions, affecting an estimated 80-98% of postpubertal women. Innovative treatments for cellulite dimpling in the buttocks have gained popularity in recent years, seeking new solutions for a historically challenging condition. In this open-label, investigator-initiated, single-center, prospective clinical study, the authors sought to evaluate the safety and efficacy of diluted calcium hydroxylapatite (CaHA; Radiesse®, Merz Aesthetics, Raleigh, NC) for the treatment of cellulite dimpling in the buttocks of adult women. METHODS: Subjects underwent three treatment sessions, receiving a total of 12 syringes of 1:1 diluted CaHA administered using a cannula-based subcision technique. Endpoints included the cellulite severity scale (CSS), the global aesthetic improvement scale (GAIS), subject satisfaction measured on a 5-point scale, and three-dimensional imaging analysis via the Quantificare 3D Track®. RESULTS: Twenty-four subjects completed the study (mean age, 35 years; mean BMI, 26.88 kg/m2; mean body fat percentage, 31.29%), and no serious complications were reported. Quantitative analysis at week 14 revealed a mean reduction of 54.0% in the number of visible dimples and 50.09% in dimple depth compared to baseline. The mean CSS score decreased by 4.29 points, representing a 43.92% improvement in cellulite severity from baseline (p < 0.0001). Both physician-assessed and subject-assessed GAIS ratings also demonstrated significant improvement, with 91.6% of subjects rating their cellulite appearance as "improved" or greater. CONCLUSION: The results of this study support the safety and efficacy of diluted CaHA for treating cellulite dimpling in adult women. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 . CLINICAL TRIALS REGISTRATION: This study is registered with clinicaltrials.gov (ID: NCT05885035) and can be found at this link: https://clinicaltrials.gov/study/NCT05885035 .
Assuntos
Celulite , Durapatita , Humanos , Feminino , Celulite/tratamento farmacológico , Adulto , Estudos Prospectivos , Durapatita/administração & dosagem , Nádegas , Resultado do Tratamento , Estética , Satisfação do Paciente/estatística & dados numéricos , Pessoa de Meia-Idade , Técnicas Cosméticas , Adulto Jovem , Materiais BiocompatíveisRESUMO
Non-surgical rhinoplasty, also known as liquid or injection rhinoplasty, utilizes hyaluronic acid-based fillers to offer a minimally invasive alternative to surgical rhinoplasty. Patient goals for injection rhinoplasty include improving various aspects of their nose, including the bridge of the nose, tip of the nose, shape of the nose in profile, and how well the nose suits the face. The purpose of this study is to use a modified surgical rhinoplasty questionnaire to analyze patient satisfaction and adverse complication rates of the authors' non-surgical injection rhinoplasty technique using a hyaluronic acid-based filler. A retrospective data analysis of 56 patients who had received a graft-based non-surgical rhinoplasty procedure between January 2019 and December 2019 was conducted. All procedures were performed at a single center by the primary investigator. Participants completed a questionnaire to assess for preoperative and postoperative satisfaction with their nose using a visual analog scale and modified "FACE-Q" module. Two-tailed paired t-tests and confidence intervals were calculated using bootstrapping/resampling techniques. Visual analog scale results depict a paired median difference of 4, yielding a P-value of 0.00001. Results illustrate that using a graft-based non-surgical rhinoplasty technique presents a promising alternative to surgical rhinoplasty that significantly improves patient satisfaction with their nose while ensuring minimal complication rates. Over 98% of patients indicated feeling "somewhat" or "very likely" to repeat the procedure. J Drugs Dermatol. 2024;23(1):1292-1296. doi:10.36849/JDD.7073.